semaglutide and cardiovascular outcomes in obesity without diabetes journal club Semaglutide and Cardiovascular Outcomes in

For semaglutide, while the core patent (protecting the molecule itself) expires in 2026, Novo Nordisk has likely filed secondary patents on aspects like formulations, dosage regimens, or delivery mechanismspotentially extending protection into the 2030s

Journal of Pharmacology and Experimental Therapeutics, 2002, 302(3): 881-888

Since it is not a controlled substance and will not cause a positive result, there is no need for the Medical Review Officer to verify your prescription

10.1016/j.orcp.2024.02.004 77

These ensure higher standards in quality control, consistent dosing, and established safety backed by rigorous FDA assessmentsunmatched by compounded alternatives